Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX; Osteopore or the Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that the Board has appointed CEO Dr Yujing Lim as Executive Director, effective immediately.
Yujing Lim, appointed Executive Director
Dr Lim has been the Chief Executive Officer (CEO) of Osteopore since 18 July 2023, succeeding his appointment as Chief Technology Officer (CTO) in 2018 and Chief Operating Officer (COO) in 2022.
During Dr Lim’s term as CEO, has spearheaded an AUD 18.7m partnership with the Agency for Science, Technology and Research (A*STAR) and the National Dental Centre of Singapore (NDCS), overseen the signing of an exclusive distribution agreement with Top 20 medical device company Zimmer Biomet and secured regulatory access in key regions including ASEAN and the European Union (EU).
Dr Lim is a Doctor of Philosophy (PhD), Bioengineering and Biomedical Engineering graduate from Nanyang Technology University Singapore, and a Master of Engineering (Mechanical Engineering) and Tissue Engineering graduate from the National University of Singapore.
In 2022, Dr Lim was recognised by Pharma Intelligence as one of the 30 people to watch across the biopharma, medtech and healthtech sectors in In Vivo’s Rising Leaders.
Commenting on Dr Lim’s appointment as Executive Director, Osteopore Executive Chairman Mark Leong, said:
“Yujing is Osteopore born-and-bred, having dedicated his career to the Company’s growth and success. As CEO, he has driven our commercialisation strategy to new heights, achieving record-breaking revenue with six consecutive quarters of growth, all whilst streamlining our cost structure.
“Under his leadership, we’ve secured key regulatory approvals and successfully launched new applications of our cutting-edge regenerative technology. His strategic insight and unwavering commitment to Osteopore make him a powerful addition to our board, as we continue to push the envelope with regenerative medicine,” said Mr Leong.
